methyl (S)-2-benzamido-3-(4-(benzyloxy)phenyl)propanoate | 231951-85-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (S)-2-benzamido-3-(4-(benzyloxy)phenyl)propanoate
• 英文别名: methyl (2S)-2-benzamido-3-(4-phenylmethoxyphenyl)propanoate
• CAS: 231951-85-2
• 化学式: C₂₄H₂₃NO₄
• 分子量: 389.451
• InChiKey: JJEQVMCXSWLAFG-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (S)-2-benzamido-3-(4-(benzyloxy)phenyl)propanoate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以90.7%的产率得到2S-benzoylamino-3-(4-benzyloxyphenyl)propionic acid
  参考文献：
  名称：

  Design, synthesis and evaluation of novel metalloproteinase inhibitors based on l-tyrosine scaffold

  摘要：

  A series of novel L-tyrosine derivatives were designed, synthesized and assayed for their inhibitory activities on matrix metalloproteinase 2 (MMP-2) and histone deacetylase 8 (HDAC-8). The results showed that these L-tyrosine derivatives exhibited inhibitory profiles against MMP-2 and HDAC-8. The compounds 6h (IC50 = 0.013 +/- 0.001 mu M) and 6j (IC50 = 0.017 +/- 0.001 mu M) were equal potent MMP-2 inhibitors to the positive control NNGH (IC50 = 0.014 +/- 0.001 mu M). As for HDAC-8 inhibition, some of the hydroxamate compounds, such as 6d (IC50 = 3.6 +/- 0.2 mu M) and 6c (IC50 = 5.8 +/- 0.5 mu M), were equal potent to the positive control SAHA (IC50 = 1.6 +/- 0.1 mu M). Structure-activity relationships were also briefly discussed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.08.014
• 作为产物：
  描述：

  Boc-L-酪氨酸甲酯 在 sodium carbonate 、 potassium carbonate 、 三氟乙酸 、 sodium iodide 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 33.0h， 生成 methyl (S)-2-benzamido-3-(4-(benzyloxy)phenyl)propanoate
  参考文献：
  名称：

  Design, synthesis and evaluation of novel metalloproteinase inhibitors based on l-tyrosine scaffold

  摘要：

  A series of novel L-tyrosine derivatives were designed, synthesized and assayed for their inhibitory activities on matrix metalloproteinase 2 (MMP-2) and histone deacetylase 8 (HDAC-8). The results showed that these L-tyrosine derivatives exhibited inhibitory profiles against MMP-2 and HDAC-8. The compounds 6h (IC50 = 0.013 +/- 0.001 mu M) and 6j (IC50 = 0.017 +/- 0.001 mu M) were equal potent MMP-2 inhibitors to the positive control NNGH (IC50 = 0.014 +/- 0.001 mu M). As for HDAC-8 inhibition, some of the hydroxamate compounds, such as 6d (IC50 = 3.6 +/- 0.2 mu M) and 6c (IC50 = 5.8 +/- 0.5 mu M), were equal potent to the positive control SAHA (IC50 = 1.6 +/- 0.1 mu M). Structure-activity relationships were also briefly discussed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.08.014

文献信息

• 10.1021/acs.joc.4c00988
  作者：Bag, Raghunath、Sharma, Nagendra K.

  DOI：10.1021/acs.joc.4c00988

  日期：——

  a Pd-catalyzed picolinamide-directed site-selective C(sp2)–H sulfonylation of amino acids and peptides with sodium sulfinates in moderate to good yields. Sulfonylation of levodopa and dopamine drug molecules and late-stage directed peptide sulfonylation are studied for the first time. Broad substrate scope having various functionalities, late-stage drug modifications, and various post synthetic utilities

  本报告描述了 Pd 催化的吡啶甲酰胺定向位点选择性 C（sp2）-H 氨基酸和肽与亚磺酸钠的磺酰化反应，产率中等至良好。首次研究了左旋多巴和多巴胺药物分子的磺酰化以及晚期定向肽磺酰化。潜在的优势包括具有各种功能的广泛底物范围、后期药物修饰以及各种合成后实用程序，如硫属化、溴化、烯化和芳基化。
• Design, synthesis and evaluation of novel metalloproteinase inhibitors based on l-tyrosine scaffold
  作者：Xian-Chao Cheng、Run-Ling Wang、Zhen-Ke Dong、Jing Li、Yao-Yuan Li、Rong-Rong Li

  DOI：10.1016/j.bmc.2012.08.014

  日期：2012.10

  A series of novel L-tyrosine derivatives were designed, synthesized and assayed for their inhibitory activities on matrix metalloproteinase 2 (MMP-2) and histone deacetylase 8 (HDAC-8). The results showed that these L-tyrosine derivatives exhibited inhibitory profiles against MMP-2 and HDAC-8. The compounds 6h (IC50 = 0.013 +/- 0.001 mu M) and 6j (IC50 = 0.017 +/- 0.001 mu M) were equal potent MMP-2 inhibitors to the positive control NNGH (IC50 = 0.014 +/- 0.001 mu M). As for HDAC-8 inhibition, some of the hydroxamate compounds, such as 6d (IC50 = 3.6 +/- 0.2 mu M) and 6c (IC50 = 5.8 +/- 0.5 mu M), were equal potent to the positive control SAHA (IC50 = 1.6 +/- 0.1 mu M). Structure-activity relationships were also briefly discussed. (C) 2012 Elsevier Ltd. All rights reserved.